Programme for Translational Hematology

The overall vision of DanStem is to obtain fundamental insights into stem cell biology and facilitate the translation of these into medical practice.

The Program for Translational Hematology (PTH) is aiming at improving the immediate and long-term outcome for blood cancer patients

The vision of PTH

Is to improve the survival of patients with blood cancers. We wish to optimize the use of already approved drugs, identify new targets for therapy, develop novel therapies, test potential novel drugs in pre-clinical models, and collaborate with pharmaceutical companies on developing new drugs and test these and other novel drugs in Phase I-II clinical trials.

The mission of PTH 

Is to coordinate and strengthen ongoing blood cancer research into a program pursuing research questions and integrating results from bed-to-benchside and bench-to-bedside.

Programme Management and Group Leaders 

Kristian Helin, DanStem, BRIC, Professor and Director
Bo Porse, DanStem, BRIC/Finsen, Professor and Director
Kirsten Grønbæk, BRIC/Rigshospitalet, Professor, MD.
Kim Theilgaard-Mönch, BRIC/Rigshospitalet, Associate Professor, MD.
Krister Wennerberg, BRIC/Rigshospitalet, Professor
Kyoung-Jae Won, BRIC, Associate Professor for Bioinformatics. 

Overall goals 

  • Having an immediate impact on how patients are treated today.
  • Improving the understanding of genetic, epigenetic and molecular mechanisms leading to blood cancers.
  • Suggesting new validated targets for the development of anti-cancer therapy.
  • Strengthening both the short- and long-term research and clinical management of blood cancer.
  • Improving the overall outcome of treatment for blood cancer patients.

Specific objectives 

  • Identification of cancer stem cells in blood cancers.
  • Establishing a platform to identify the best currently available therapies for the individual patient over the course of the disease.
  • Development of pre-clinical mouse and PDX models for blood cancer.
  • Identification and validation of novel targets for the treatment of blood cancer.
  • Implementing collaborations with biotech and the pharmaceutical industry to develop new drugs for the treatment of blood cancers.
  • Improving the education of the next generation of clinicians and scientists working on blood cancers.